Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arsanis Inc (ASNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8199
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arsanis Inc (Arsanis) is a clinical-stage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company’s pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets respiratory syncytial virus (RSV); ASN300, for klebsiella pneumonia; and ASN200, for escherichia coli. Arsanis works in collaboration with industry, academic and clinical research groups for antibody discovery and development. The company is funded by SV Life Sciences, OrbiMed, NeoMed, Polaris Ventures, and EMBL Ventures among others. It has operational presence in the US and Austria. Arsanis is headquartered in Waltham, Massachusetts, the US.

Arsanis Inc (ASNS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
Licensing Agreements 17
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Equity Offering 20
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Debt Offering 25
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc – Key Competitors 28
Arsanis Inc – Key Employees 29
Arsanis Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 13, 2018: Arsanis Reports Financial Results for Second Quarter 2018 31
May 10, 2018: Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 33
Mar 09, 2018: Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 35
Corporate Communications 37
Oct 04, 2017: Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer 37
Product News 38
04/17/2018: Arsanis to Present Abstract On ASN500 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 38
04/17/2018: Arsanis to Present Poster On ASN100 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 39
Clinical Trials 40
Oct 09, 2017: Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017 40
Sep 08, 2017: Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance” 41
Apr 20, 2017: Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Disease 42
Jan 24, 2017: Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Arsanis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc, Key Competitors 28
Arsanis Inc, Key Employees 29
Arsanis Inc, Subsidiaries 30

List of Figures
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Oando Plc (OANDO):企業の財務・戦略的SWOT分析
    Oando Plc (OANDO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Veritas (India) Ltd:企業の戦略・SWOT・財務分析
    Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report Summary Veritas (India) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Hitachi Construction Machinery Co., Ltd. (6305):企業の財務・戦略的SWOT分析
    Hitachi Construction Machinery Co., Ltd. (6305) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Robert Half International Inc (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pepsi-Cola Products Philippines Inc:戦略・SWOT・企業財務分析
    Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report Summary Pepsi-Cola Products Philippines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • United Supermarkets LLC:企業の戦略・SWOT・財務情報
    United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report Summary United Supermarkets LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Dunelm Group plc (DNLM):企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Qatar National Bank (QNBK):企業の財務・戦略的SWOT分析
    Qatar National Bank (QNBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • A. Menarini Industrie Farmaceutiche Riunite Srl:企業の戦略的SWOT分析
    A. Menarini Industrie Farmaceutiche Riunite Srl - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competito …
  • Elbit Systems Ltd:企業の戦略・SWOT・財務情報
    Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary Elbit Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Alliance Pipeline LP:企業の戦略的SWOT分析
    Alliance Pipeline LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Energy XXI Gulf Coast Inc (EXXIQ):企業の財務・戦略的SWOT分析
    Summary Energy XXI Gulf Coast Inc (Energy XXI) is an oil and gas company that explores and develops oil and natural gas assets. The company’s projects include West Delta, South Timbalier, South Pass, Main Pass, and Ship Shoal. Its West Delta property is located 28 miles offshore of Grand Isle, Louis …
  • Gulf Resources, Inc. (GURE):企業の財務・戦略的SWOT分析
    Gulf Resources, Inc. (GURE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • ExlService Holdings, Inc.:企業の戦略・SWOT・財務情報
    ExlService Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary ExlService Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Salter Labs:医療機器:M&Aディール及び事業提携情報
    Summary Salter Labs (Salter) is a medical device company that offers HME, home, and acute care products. The company offers products such as whisper and silhouette cannula, swivel connector, static connector and humidifier tubing, among others. It also provides visible tubing, petite cannula sensiti …
  • Chesapeake Energy Corp (CHK):企業の財務・戦略的SWOT分析
    Chesapeake Energy Corp (CHK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Charles River Laboratories International Inc (CRL)-医療機器分野:企業M&A・提携分析
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • CG Power and Industrial Solutions Ltd (CGPOWER):企業の財務・戦略的SWOT分析
    CG Power and Industrial Solutions Ltd (CGPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key st …
  • Berkshire Hathaway Inc.:企業のM&A・事業提携・投資動向
    Berkshire Hathaway Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Berkshire Hathaway Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • SBI Holdings Inc (8473):企業の財務・戦略的SWOT分析
    SBI Holdings Inc (8473) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆